This action will enable patients currently enrolled in the Assist-3 and Assist-5 trials the opportunity to continue to receive study treatments, including Telcyta in combination with chemotherapy, subject to re-consenting procedures.
Telik says it continues to work closely with the FDA in its review of Telcyta.
Telcyta is a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, Telintra, is in clinical development for myelodysplastic syndrome.